Challenges in Implementing Treat-to-Target Strategies in Rheumatology.

[1]  J. Sparks,et al.  Mobile Apps for Individuals With Rheumatoid Arthritis: A Systematic Review , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[2]  K. Michaud,et al.  Rheumatoid Arthritis Patients’ Motivations for Accepting or Resisting Disease‐Modifying Antirheumatic Drug Treatment Regimens , 2018, Arthritis care & research.

[3]  L. Fraenkel,et al.  Implementation of Treat‐to‐Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial , 2017, Arthritis & rheumatology.

[4]  J. Beaumont,et al.  Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities , 2017, Clinical Rheumatology.

[5]  P. V. van Riel,et al.  Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study , 2017, Annals of the rheumatic diseases.

[6]  L. Duley,et al.  OP0268 Nurse-led care versus general practitioner care of people with gout: a uk community-based randomised controlled trial , 2017 .

[7]  E. Morand,et al.  Treat to target, remission and low disease activity in SLE. , 2017, Best practice & research. Clinical rheumatology.

[8]  A. Qaseem,et al.  Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. , 2017, Annals of internal medicine.

[9]  M. Weisman,et al.  Treat-to-target (T2T) recommendations for gout , 2016, Annals of the rheumatic diseases.

[10]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[11]  L. Fraenkel,et al.  Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. , 2016, Seminars in arthritis and rheumatism.

[12]  K. Michaud,et al.  Patient-Reported Outcomes in Rheumatoid Arthritis. , 2016, Rheumatic diseases clinics of North America.

[13]  M. Dougados,et al.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update , 2015, Annals of the rheumatic diseases.

[14]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[15]  L. Fraenkel,et al.  Comparison of Care Provided in Practices With Nurse Practitioners and Physician Assistants Versus Subspecialist Physicians Only: A Cohort Study of Rheumatoid Arthritis , 2015, Arthritis care & research.

[16]  M. Hochberg,et al.  Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events , 2015, Arthritis & rheumatology.

[17]  L. Fraenkel,et al.  Roles of Nurse Practitioners and Physician Assistants in Rheumatology Practices in the US , 2014, Arthritis care & research.

[18]  Helena Canhão,et al.  FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries , 2014 .

[19]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.

[20]  Jeffrey N Katz,et al.  Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis? , 2014, Arthritis & rheumatology.

[21]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[22]  M. Dougados,et al.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force , 2013, Annals of the rheumatic diseases.

[23]  M. Dougados,et al.  Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis , 2013, Annals of the rheumatic diseases.

[24]  J. Schoones,et al.  What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review , 2013, Annals of the rheumatic diseases.

[25]  D. Elashoff,et al.  Regional distribution of adult rheumatologists. , 2013, Arthritis and rheumatism.

[26]  D. Solomon,et al.  Patterns of Disease‐Modifying Antirheumatic Drug Use in Rheumatoid Arthritis Patients After 2002: A Systematic Review , 2013, Arthritis care & research.

[27]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[28]  Jeffrey R Curtis,et al.  2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.

[29]  J. Kremer,et al.  Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. , 2012, Arthritis and rheumatism.

[30]  J. Katz,et al.  Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey , 2012, Arthritis care & research.

[31]  D. Solomon,et al.  Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement , 2011, Arthritis research & therapy.

[32]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[33]  M. Dougados,et al.  Extended report: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search , 2010 .

[34]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[35]  A. McMahon,et al.  Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. , 2008, Arthritis and rheumatism.

[36]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. , 2008, Arthritis and rheumatism.

[37]  F. Wolfe,et al.  Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. , 2007, Arthritis and rheumatism.

[38]  J. Jacobs,et al.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) , 2007, Annals of the rheumatic diseases.

[39]  R. Hooker,et al.  The United States rheumatology workforce: supply and demand, 2005-2025. , 2007, Arthritis and rheumatism.

[40]  D. Symmons,et al.  The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. , 2005, Health technology assessment.

[41]  P. V. van Riel,et al.  Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial , 2005, Annals of the rheumatic diseases.

[42]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[43]  J. Frytak,et al.  Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. , 2003, The American journal of managed care.

[44]  T W Nolan,et al.  Reducing adverse drug events: lessons from a breakthrough series collaborative. , 2000, The Joint Commission journal on quality improvement.

[45]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.